<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05001048</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00088122</org_study_id>
    <nct_id>NCT05001048</nct_id>
  </id_info>
  <brief_title>Sex Differences in Sympathetic Activity and Vascular Reactivity During Acute and Chronic Hypoxia.</brief_title>
  <official_title>Sex Differences in Sympathetic Activity and Vascular Reactivity During Acute and Chronic Hypoxia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate sex differences in blood pressure control associated with&#xD;
      exposure to acute hypoxia (low oxygen), and short term acclimatization to hypoxia at high&#xD;
      altitude.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      About 200 million people worldwide live at high altitudes. Millions of others travel to high&#xD;
      altitude every year for work or travel. The low oxygen (or hypoxia) experienced at high&#xD;
      altitudes causes considerable physiological stress, and the body adapts in order to maintain&#xD;
      adequate oxygen delivery to its tissues. One of these adaptations is an increase in the&#xD;
      activity of the sympathetic nervous system. This system is responsible for the &quot;fight or&#xD;
      flight&quot; response. Sympathetic activity regulates the size of the blood vessels, which will&#xD;
      affect blood pressure. Previous studies suggest that males and females regulate their blood&#xD;
      pressure in different ways. Females tend to have lower resting sympathetic activity, and less&#xD;
      vasoconstriction in response to stressors than males. Blood pressure changes are also&#xD;
      influenced by levels of sex hormones; for example, estrogen may cause opposing vasodilation.&#xD;
      Therefore, it is important to understand the differences in how males and females respond to&#xD;
      low oxygen.&#xD;
&#xD;
      The main purpose of this study is to examine the differences between males and females in&#xD;
      control of blood vessels during exposure to low oxygen. To study this question, we will test&#xD;
      vasoreactivity to set physiological stressors in both males and females. Participants will be&#xD;
      recruited at the Canadian sites, and we will test them while they breathe low oxygen for a&#xD;
      short amount of time at low altitude. We will also perform assessments on the same&#xD;
      participants during a two week stay at high altitude at White Mountain, CA, which is at an&#xD;
      altitude of 3,800m. These data will have implications in the basic understanding of&#xD;
      differences between male and female physiology. Specifically, to males and females living or&#xD;
      travelling to high altitude.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 4, 2019</start_date>
  <completion_date type="Actual">December 7, 2020</completion_date>
  <primary_completion_date type="Actual">December 7, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Participants will partake in all three arms of the study, which include: 1) low altitude, 2) early acclimatization, and 3) late acclimatization to high altitude assessments.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Due to the study design, masking is not possible. The time points and dosages of the study drug will be known to the participant. Further, due to the wash-out time of the acute hypoxia/hyperoxia interventions, these will always be completed second to the interventions breathing room air.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in blood pressure</measure>
    <time_frame>18 minutes</time_frame>
    <description>Phenylephrine sensitivity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in arterial blood flow</measure>
    <time_frame>18 minutes</time_frame>
    <description>Phenylephrine sensitivity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cold pressor test reactivity</measure>
    <time_frame>4 minutes</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Vasodilation</condition>
  <condition>Vasoconstriction</condition>
  <arm_group>
    <arm_group_label>Low Altitude</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be assessed at an altitude of &lt;1050m.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Early Acclimatization to High Altitude</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be assessed on day 2 or 3 of a high-altitude expedition at 3,800m.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Late Acclimatization to High Altitude</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be assessed on day 9 or 10 of a high-altitude expedition at 3,800m.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenylephrine Hydrochloride</intervention_name>
    <description>Series of three incremental bolus injections to observe α1-adrenoreceptor mediated vasoconstriction.</description>
    <arm_group_label>Early Acclimatization to High Altitude</arm_group_label>
    <arm_group_label>Late Acclimatization to High Altitude</arm_group_label>
    <arm_group_label>Low Altitude</arm_group_label>
    <other_name>Neo-Synephrine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cold Pressor Test</intervention_name>
    <description>Standardized sympathetic stressor involving submersion of the hand in ice-cold water for 3-minutes, aiming to elicit endogenous neurotransmitter release and blood pressure increases.</description>
    <arm_group_label>Early Acclimatization to High Altitude</arm_group_label>
    <arm_group_label>Late Acclimatization to High Altitude</arm_group_label>
    <arm_group_label>Low Altitude</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Isocapnic Acute Hypoxia</intervention_name>
    <description>During low altitude assessment, participants will be exposed to isocapnic hypoxia equivalent to 3,800m to assess responses to acute exposure.</description>
    <arm_group_label>Low Altitude</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hyperoxia</intervention_name>
    <description>During high altitude assessments, participants will breathe an oxygen concentration comparable to their end-tidal values at low altitude for the assessment of the influences of acclimatization.</description>
    <arm_group_label>Early Acclimatization to High Altitude</arm_group_label>
    <arm_group_label>Late Acclimatization to High Altitude</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Between ages of 18-50&#xD;
&#xD;
          -  No medical history of cardiovascular, respiratory, nervous system, or metabolic&#xD;
             disease&#xD;
&#xD;
          -  Females must be pre-menopausal&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any known cardiovascular, respiratory, nervous system, or metabolic disease (however,&#xD;
             participants with controlled arterial hypertension will not be excluded)&#xD;
&#xD;
          -  Having travelled above 2,000m within 1 month of testing at low and high altitude&#xD;
&#xD;
          -  Females who are pregnant, confirmed by a pregnancy test&#xD;
&#xD;
          -  Females who are post-menopausal&#xD;
&#xD;
          -  Participants that are classified as obese (body mass index &gt; 30kg⋅m²)&#xD;
&#xD;
          -  Have a history of smoking regularly in the last 6 months (but nicotine substitutes&#xD;
             (patch, gum) not an exclusion criteria)&#xD;
&#xD;
          -  Those with a known allergy to sulfites&#xD;
&#xD;
          -  Participants taking monoamine oxidase (MAO) inhibitors or tricyclic antidepressants&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean van Diepen, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Craig Steinback, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Royal University</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3E 6K6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2R3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Hart EC, Charkoudian N, Wallin BG, Curry TB, Eisenach JH, Joyner MJ. Sex differences in sympathetic neural-hemodynamic balance: implications for human blood pressure regulation. Hypertension. 2009 Mar;53(3):571-6. doi: 10.1161/HYPERTENSIONAHA.108.126391. Epub 2009 Jan 26.</citation>
    <PMID>19171792</PMID>
  </reference>
  <reference>
    <citation>Mazzeo RS, Child A, Butterfield GE, Mawson JT, Zamudio S, Moore LG. Catecholamine response during 12 days of high-altitude exposure (4, 300 m) in women. J Appl Physiol (1985). 1998 Apr;84(4):1151-7.</citation>
    <PMID>9516178</PMID>
  </reference>
  <reference>
    <citation>Purdy GM, James MA, Rees JL, Ondrus P, Keess JL, Day TA, Steinback CD. Spleen reactivity during incremental ascent to altitude. J Appl Physiol (1985). 2019 Jan 1;126(1):152-159. doi: 10.1152/japplphysiol.00753.2018. Epub 2018 Nov 21.</citation>
    <PMID>30462566</PMID>
  </reference>
  <reference>
    <citation>Usselman CW, Gimon TI, Nielson CA, Luchyshyn TA, Coverdale NS, Van Uum SH, Shoemaker JK. Menstrual cycle and sex effects on sympathetic responses to acute chemoreflex stress. Am J Physiol Heart Circ Physiol. 2015 Mar 15;308(6):H664-71. doi: 10.1152/ajpheart.00345.2014. Epub 2014 Dec 19.</citation>
    <PMID>25527774</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 4, 2021</study_first_submitted>
  <study_first_submitted_qc>August 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2021</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Synephrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

